Softwr

Research · head to head

Dotmatics vs Greenphire

Dotmatics logo

Dotmatics

Research

Research informatics group behind GraphPad Prism, SnapGene, Geneious and LabArchives, now owned by Siemens

From
On request
Rated
-
Full reviewWebsite
Greenphire logo

Greenphire

Research

Clinical trial participant payments, reimbursement and travel, now part of Suvoda

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Dotmatics the portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.; Greenphire the standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.
  • They diverge on capability: Dotmatics covers Dotmatics platform, Greenphire covers ClinCard.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Dotmatics and Greenphire actually diverge.

Attributes where Dotmatics and Greenphire differ
AttributeDotmaticsGreenphire
PlatformsWeb, Windows, macOS, On-premiseWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Dotmatics

  • Dotmatics platform
  • GraphPad Prism
  • SnapGene
  • Geneious Prime and Biologics
  • LabArchives
  • Flow cytometry tools
  • Protein Metrics
  • Siemens ownership

Only in Greenphire

  • ClinCard
  • Direct to bank payment
  • Expense reimbursement
  • Travel and logistics
  • Site payments
  • Budgeting and benchmarking
  • Tax handling

What people use each for

The jobs each tool is most often brought in to do.

Dotmatics

  • A pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layernot Greenphire
  • A biotech that already owns Prism, SnapGene and Geneious separately and wants to understand what a group contract would covernot Greenphire
  • A university licensing LabArchives across departments as an institutional electronic lab notebooknot Greenphire
  • A biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement routenot Greenphire

Greenphire

  • A global Phase III trial paying stipends across many countries where participants cannot practically be reimbursed by sponsor accounts payablenot Dotmatics
  • A decentralised or hybrid trial where participants travel long distances and the sponsor funds flights and accommodationnot Dotmatics
  • A trial in a population where slow reimbursement drives dropout and same day payment materially helps retentionnot Dotmatics
  • A sponsor that wants site payment milestones and participant payments handled by one vendor rather than twonot Dotmatics

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Dotmatics

  • The portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.
  • The Siemens acquisition completed in July 2025 with stated revenue synergy targets, which usually translates into pressure to move individually bought desktop licences into larger platform agreements, and small buyers of a single Prism or SnapGene seat should expect that pressure at renewal.
  • Nothing about the enterprise platform is publicly priced, and even the individual applications are increasingly moved to subscription, so total cost across a research group is hard to establish before negotiation.
  • Each acquired product retains its own licence terms, support channel and release cycle, so an organisation using four Dotmatics brands manages four different renewal dates, entitlement models and support experiences.
  • Enterprise deployments require data migration and configuration services, and validated instances for regulated use add both cost and an ongoing customer revalidation duty after each release, so the informatics platform is a programme rather than a purchase.

Greenphire

  • The standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.
  • Nothing is published on price, and the typical shape of a platform fee plus per participant and per transaction charges means the cost of a trial is not knowable until enrolment is known.
  • Payment method availability varies sharply by country, so a global protocol may end up with card payments in some regions and slow manual processes in others, which undermines the retention argument that justified the purchase.
  • Sites bear the administrative work of enrolling participants and triggering payments but are not the buyer, so adoption depends on the sponsor mandating it and site resistance is a real implementation risk.
  • Participant payments create tax reporting obligations that differ per jurisdiction, and the tooling helps but does not remove sponsor liability, so legal and finance review is required in every country the trial runs in.

Pricing, plan by plan

Dotmatics

On request
  • Dotmatics platform$undefined/year
    • Enterprise informatics platform priced per user per year on quotation
    • Chemistry and biology registration, assay data and ELN modules scoped separately
    • Implementation and data migration services quoted as a separate programme

Greenphire

On request
  • Greenphire Patient Payments$undefined/year
    • Priced per study through a sales process
    • Typically a platform fee plus per participant and per transaction charges
    • Funding of the payment float is separate from the software fee

Which should you pick?

Choose Dotmatics if

  • You need dotmatics platform.
  • You work on Web, Windows, macOS, On-premise.
  • You also want graphpad prism.
Dotmatics review

Choose Greenphire if

  • You need clincard.
  • You work on Web, iOS, Android.
  • You also want direct to bank payment.
Greenphire review

Questions people ask

Is Dotmatics or Greenphire better?
Neither clearly leads. Dotmatics starts at On request and Greenphire at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Dotmatics or Greenphire?
Dotmatics starts at On request and Greenphire at On request.
Does Dotmatics or Greenphire run on more platforms?
Dotmatics runs on Web, Windows, macOS, On-premise. Greenphire runs on Web, iOS, Android.
What is Dotmatics best used for?
Dotmatics is most often used for a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer, a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover, a university licensing labarchives across departments as an institutional electronic lab notebook, a biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement route. Of those, a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer and a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover are not what Greenphire is typically brought in for.
What can Dotmatics do that Greenphire cannot?
Dotmatics covers Dotmatics platform, GraphPad Prism, SnapGene, Geneious Prime and Biologics. Greenphire covers ClinCard, Direct to bank payment, Expense reimbursement, Travel and logistics.

Answered from the vendors’ own pages

Dotmatics: Who owns Dotmatics?

Siemens, which completed a 5.1 billion dollar acquisition on 1 July 2025. Dotmatics now sits inside Siemens Digital Industries Software.

Greenphire: Is Greenphire still sold?

Yes, as Greenphire Patient Payments on the Suvoda platform. The independent website and social presence have been consolidated into Suvoda.

Dotmatics: Is GraphPad Prism a Dotmatics product?

Yes. So are SnapGene, Geneious, LabArchives, FCS Express, OMIQ, Protein Metrics, SoftGenetics and nQuery.

Greenphire: What is ClinCard?

The reloadable debit card Greenphire issues to participants. Greenphire Patient Payments was formerly known as ClinCard.

Dotmatics: Do the products work together?

To varying degrees. They were acquired separately and integration across the portfolio is uneven, so verify the specific pair you care about before assuming it.

Greenphire: Does it publish pricing?

No. Pricing is per study and quoted through sales, and funding the payments themselves is separate from the software fee.

Dotmatics: Is enterprise pricing published?

No. The informatics platform is quoted per user per year with modules and services scoped separately.

Greenphire: Can it pay participants outside the United States?

Yes, in more than thirty currencies, but the available payment method depends on the country.

Share

Related pages

More on Dotmatics

More on Greenphire

Keep looking

Other head to heads